Toll-like receptors in natural killer cells and their application for immunotherapy
Is post-cycle therapy required after stopping
However, at present, GLP-1 agonists are not formally prescribed specifically to treat arthritis
The DPP4i class comprises a heterogeneous group of unrelated compounds with differing pharmacokinetic profiles
By unearthing unexpected juxtapositions, we act as a catalyst for creativity
The choice of add-on therapy, however, should be based on patient-specific variables, such as the risk of developing hypoglycemia and any associated adverse consequences, relative need to avoid weight gain, existing comorbidity profile, financial resources and personal support systems available, and the patients overall motivation to pursue lifestyle changes and maintain regimen adherence